WERI-Rb-1人视网膜神经胶质瘤细胞

价 格:¥1800

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1202

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line nameWERI-Rb-1
SynonymsWERI-RB-1; WERI-Rb 1; WERI-Rb1; WERI-RB1; WERI Rb-1; WERIRb1; WERI; Wills Eye Research Institute-Retinoblastoma-1
AccessionBTCC-1202
Secondary accessionBTCC-1202
Resource Identification InitiativeTo cite this cell line use: WERI-Rb-1 (BTCC-1202)
CommentsPart of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: ENCODE project common cell types; tier 3.
Population: Caucasian.
Doubling time: 96 hours (PubMed=844036); 50 hours (PubMed=25326674); 84 hours (PubMed=31781967); ~49 hours (DSMZ=ACC-90).
Omics: CTCF ChIP-seq epigenome analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: Deep quantitative proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Eye, globe; UBERON=UBERON_0010230.
Sequence variations
  • Gene deletion; HGNC; 9884; RB1; Zygosity=Homozygous (PubMed=25326674).
DiseaseRetinoblastoma (NCIt: C7541)
Retinoblastoma (ORDO: Orphanet_790)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:


CVCL_B7IE (WERI-Rb-1 CDDP-R)CVCL_B7ID (WERI-Rb-1 Eto-R)
Sex of cellFemale
Age at sampling1Y
CategoryCancer cell line
STR profileSource(s): ATCC; DepMap; DSMZ; JCRB; RCB; TKG

Markers:
AmelogeninX
CSF1PO10 (TKG)
10,12,13 (ATCC; DepMap; DSMZ; RCB)
11,12 (JCRB)
D2S133812,15
D3S135814,15
D5S81811,12
D7S82010,12,13 (JCRB)
10,13 (ATCC; DepMap; DSMZ; RCB; TKG)
D8S117912,15
D13S31714
D16S53913
D18S5113,19
D19S43314,15
D21S1129
FGA21
Penta D12,13
Penta E7,11
TH019.3
TPOX8,11
vWA17,18

Run an STR similarity search on this cell line
Web pageshttp://genome.ucsc.edu/ENCODE/protocols/cell/human/WERI-Rb-1_Stam_protocol.pdf
Publications

PubMed=844036
McFall R.C., Sery T.W., Makadon M.
Characterization of a new continuous cell line derived from a human retinoblastoma.
Cancer Res. 37:1003-1010(1977)

PubMed=679190
McFall R.C., Nagy R.M., Nagle B.T., McGreevy L.M.
Scanning electron microscopic observation of two retinoblastoma cell lines.
Cancer Res. 38:2827-2835(1978)

PubMed=6351622; DOI=10.1016/S0002-9394(14)77822-5
Ohashi Y., Sasabe T., Nishida T., Nishi Y., Higashi H.
Hanganutziu-Deicher heterophile antigen in human retinoblastoma cells.
Am. J. Ophthalmol. 96:321-325(1983)

DOI=10.5795/jjscc.24.451
Tsumuraya M., Nakajima T., Terasaki T., Kodama T., Shimosato Y., Higuchi H., Uei Y.
Analysis of LDH isoenzyme patterns in cell lines of the small cell carcinoma (lung) and retinoblastoma.
Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985)

PubMed=2751270
Chan H.S.L., Canton M.D., Gallie B.L.
Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines.
Anticancer Res. 9:469-474(1989)

PubMed=1682862; DOI=10.1016/S0161-6420(91)32134-1
Chan H.S.L., Thorner P.S., Haddad G., Gallie B.L.
Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression.
Ophthalmology 98:1425-1431(1991)

PubMed=7689221; DOI=10.1073/pnas.90.16.7578
Godbout R., Squire J.A.
Amplification of a DEAD box protein gene in retinoblastoma cell lines.
Proc. Natl. Acad. Sci. U.S.A. 90:7578-7582(1993)

PubMed=7499444; DOI=10.1007/BF01213319
Inomata M., Saijo N., Kawashima K., Kaneko A., Fujiwara Y., Kunikane H., Tanaka Y.
Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid.
J. Cancer Res. Clin. Oncol. 121:729-738(1995)

PubMed=19686387; DOI=10.1111/j.1471-4159.2009.06322.x
Glubrecht D.D., Kim J.-H., Russell L., Bamforth J.S., Godbout R.
Differential CRX and OTX2 expression in human retina and retinoblastoma.
J. Neurochem. 111:250-263(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=23498719; DOI=10.1016/S1470-2045(13)70045-7
Rushlow D.E., Mol B.M., Kennett J.Y., Yee S., Pajovic S., Theriault B.L., Prigoda-Lee N.L., Spencer C., Dimaras H., Corson T.W., Pang R., Massey C., Godbout R., Jiang Z., Zacksenhaus E., Paton K., Moll A.C., Houdayer C., Raizis A., Halliday W., Lam W.L., Boutros P.C., Lohmann D., Dorsman J.C., Gallie B.L.
Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.
Lancet Oncol. 14:327-334(2013)

PubMed=25326674; DOI=10.1007/s00418-014-1285-z
Busch M., Philippeit C., Weise A., Dunker N.
Re-characterization of established human retinoblastoma cell lines.
Histochem. Cell Biol. 143:325-338(2015)

PubMed=27115612; DOI=10.1371/journal.pone.0153323
Kooi I.E., Mol B.M., Massink M.P., de Jong M.C., de Graaf P., van der Valk P., Meijers-Heijboer H., Kaspers G.J.L., Moll A.C., te Riele H., Cloos J., Dorsman J.C.
A meta-analysis of retinoblastoma copy numbers refines the list of possible driver genes involved in tumor progression.
PLoS ONE 11:E0153323-E0153323(2016)

PubMed=28713896; DOI=10.3892/ijmm.2017.3058
Liu Y., Fan Z.-G., Li K., Deng F., Xiong Y.-F., Liang M.-X., Ge J.
An optimized gene transfection system in WERI-Rb1 cells.
Int. J. Mol. Med. 40:801-813(2017)

PubMed=29192327; DOI=10.3892/or.2017.6100
Busch M.A., Papior D., Stephan H., Dunker N.
Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines.
Oncol. Rep. 39:160-172(2018)

PubMed=30584916; DOI=10.1016/j.yexcr.2018.12.018
Schwermer M., Hiber M., Dreesmann S., Rieb A., Theissen J., Herold T., Schramm A., Temming P., Steenpass L.
Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
Exp. Cell Res. 375:92-99(2019)

PubMed=31781967; DOI=10.1007/s00418-019-01832-1
Ravishankar H., Mangani A.S., Shankar M.B., Joshi M., Devasena T., Parameswaran S., Subramaniam K.
Characterization of NCC-RbC-51, an RB cell line isolated from a metastatic site.
Histochem. Cell Biol. 153:101-109(2020)

PubMed=32123578; DOI=10.1038/s41420-020-0237-8
Aubry A., Yu T., Bremner R.
Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy.
Cell Death Discov. 6:2.1-2.12(2020)

PubMed=35409416; DOI=10.3390/ijms23074058
Kakkassery V., Gemoll T., Kraemer M.M., Sauer T., Tura A., Ranjbar M., Grisanti S., Joachim S.C., Mergler S., Reinhard J.
Protein profiling of WERI-RB1 and etoposide-resistant WERI-ETOR reveals new insights into topoisomerase inhibitor resistance in retinoblastoma.
Int. J. Mol. Sci. 23:4058.1-4058.14(2022)

Cross-references
Cell line databases/resourcesCLO; CLO_0009583
CLO; CLO_0009584
CLO; CLO_0051563
CLDB; cl4695
CCRID; 3101HUMTCHu213
Cell_Model_Passport; SIDM01414
DepMap; ACH-001421
DSMZCellDive; ACC-90
IGRhCellID; WERIRb1
Lonza; 1147
Biological sample resourcesBioSample; SAMN03472730
ENCODE; ENCBS087YAE
ENCODE; ENCBS270AAA
ENCODE; ENCBS282DQM
ENCODE; ENCBS283KOW
ENCODE; ENCBS283WND
ENCODE; ENCBS679NMZ
Cell line collections (Providers)AddexBio; C0029002/4899
ATCC; HTB-169
CLS; 300632
DSMZ; ACC-90
ECACC; 06070602
IZSLER; BS TCL 231
JCRB; JCRB3028
JCRB; KURB2683 - Discontinued
RCB; RCB2146
TKG; TKG 0601
Encyclopedic resourcesWikidata; Q54993776
Experimental variables resourcesEFO; EFO_0005715

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部